1[1]Bolanos-Meade J, Karp JE, Guo C, et al. Timed sequential therapy of acute myelogenous leukemia in adults: a phase Ⅱ study of retinoids in combination with the sequential administration of cytosine arabinoside,idarubicinandetoposide. Leuk Res, 2003, 27(4):313 ～ 321.
2[2]Robak T. Purine nucleoside analogues in the treatment of myleoid leukemias. Leuk Lymphoma, 2003, 44(3):391～409.
3[3]Marcucci G, Byrd JC, Dai G, et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapyin refractory or relapsed acute leukemia. Blood, 2003, 101 (2):425 ～32.
4[4]Pastore D, Specchia G, Carlaccio P, et al. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia:single-center experience. Ann Hematol, 2003, 82(4):231～235.
5[5]Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin:a Southwest Oncology Group study. Blood, 2002, 100(12):3869 ～ 3876.
6[6]Tavernier E, Le QH, Elhamri M, et al. Salvage therapy in refractory acute myeloid leukemia: prediction of outcomebasedonanalysis of prognostic factors. Leuk Res, 2003, 27(3):205～214.
3VARDIMAN J W,HARRIS N L,BRUNNING R D.World Health Organization Classification of the myeloid neoplasms[J].Blood,2002,100(7):2292-2302.
4HAROUSSEAU J L,WITZ B,LIOURE B,et al.Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia:results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques[J].J Clin Oncol,2000,18(4):780-787.
